alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
L.W., Mother of O.W. and A.W., Children, Appellant, v. DEPARTMENT OF CHILDREN AND FAMILIES, Appellee.

Case No. 5D19-575

District Court of Appeal of Florida, Fifth District.

Decision filed June 20, 2019

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1273 Introduced in House (IH)]

109th CONGRESS
  1st Session
                                H. R. 1273

    To require any amounts remaining in a Member's Representational 
 Allowance at the end of a fiscal year to be deposited in the Treasury 
     and used for deficit reduction or to reduce the Federal debt.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 14, 2005

  Mr. Kind (for himself and Mr. Kirk) introduced the following bill; 
      which was referred to the Committee on House Administration

_______________________________________________________________________

                                 A BILL

 
    To require any amounts remaining in a Member's Representational 
 Allowance at the end of a fiscal year to be deposited in the Treasury 
     and used for deficit reduction or to reduce the Federal debt.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. REQUIRING AMOUNTS REMAINING IN MEMBERS' REPRESENTATIONAL 
              ALLOWANCES TO BE USED FOR DEFICIT REDUCTION OR TO REDUCE 
              THE FEDERAL DEBT.

    (a) In General.--Notwithstanding any other provision of law, any 
amounts appropriated for Members' Representational Allowances for the 
House of Representatives for a fiscal year which remain after all 
payments are made under such Allowances for the year shall be deposited 
in the Treasury and used for deficit reduction, except that in the case 
of a fiscal year for which there is no Federal budget deficit, such 
amounts shall be used to reduce the Federal debt (in such manner as the 
Secretary of the Treasury considers appropriate).
    (b) Effective Date.--This section shall apply with respect to 
fiscal year 2005 and each succeeding fiscal year.
                                 <all>
```
Exhibit 31.1

CERTIFICATIONS

I, John M. Piecuch, certify that:

1. I have reviewed this annual report on Form 10-K of MMI Products, Inc.;
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
5. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
6. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and
7. disclosed in this report any changes in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
8. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
9. all significant deficiencies and materially weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
10. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.



|Date:   April 2, 2004 | By:   /s/John M. Piecuch                              
|--------------------- | ------------------------------------------------------
|                      | John M. Piecuch, President and Chief
Executive Officer
H. R. 1236

One Hundred Ninth Congress

of the

United States of America 

AT THE FIRST SESSION 

Begun and held at the City of Washington on Tuesday, 

the fourth day of January, two thousand and five 

An Act 

To designate the facility of the United States Postal Service located at 750 4th 

Street in Sparks, Nevada, as the ‘‘Mayor Tony Armstrong Memorial Post Office’’.

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. DESIGNATION. 

The facility of the United States Postal Service located at 

750 4th Street in Sparks, Nevada, shall be known and designated 

as the ‘‘Mayor Tony Armstrong Memorial Post Office’’. 

SEC. 2. REFERENCES. 

Any reference in a law, map, regulation, document, paper, 

or other record of the United States to the facility referred to 

in section 1 shall be deemed to be a reference to the ‘‘Mayor 

Tony Armstrong Memorial Post Office’’.

Speaker of the House of Representatives.

Vice President of the United States and

President of the Senate.
EXHIBIT 32.1



CERTIFICATION
PURSUANT TO

18 U.S.C. SECTION
1350

AS ADOPTED PURSUANT
TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002



In connection
with the Report of Seven Arts Entertainment, Inc. on Form 10-K for the period ended June 30, 2013 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), the undersigned, in the capacities and on the dates indicated
below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that to the best of his knowledge:



|1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|-- | ---------------------------------------------------------------------------------------------------------------------



|2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|Date: October 15, 2013 | By: | /s/ Kate Hoffman        | 
|---------------------- | --- | ----------------------- | 
|                       |     | Kate Hoffman            | 
|                       |     | Chief Executive Officer | 



|Date: October 15, 2013 | By: | /s/ Candace Wernick     | 
|---------------------- | --- | ----------------------- | 
|                       |     | Candace Wernick         | 
|                       |     | Chief Financial Officer | 



|Date: October 15, 2013 | By: | /s/ Candace Wernick          | 
|---------------------- | --- | ---------------------------- | 
|                       |     | Candace Wernick              | 
|                       |     | Principal Accounting Officer | 



This certification accompanies the
Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley
Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
Unassociated Document


    
      

    

    
      FORM OF
WAIVER

      


      


      In
consideration for the benefits I will receive as a result of my employer’s
participation in the United States Department of the Treasury’s TARP Capital
Purchase Program, I hereby voluntarily waive any claim against the United States
or my employer for any changes to my compensation or benefits that are required
to comply with the regulation issued by the Department of the Treasury as
published in the Federal Register on October 20, 2008.

      


      I
acknowledge that this regulation may require modification of the compensation,
bonus, incentive and other benefit plans, arrangements, policies and agreements
(including so-called “golden parachute” agreements) that I have with my employer
or in which I participate as they relate to the period the United States holds
any equity or debt securities of my employer acquired through the TARP Capital
Purchase Program.

      


      This
waiver includes all claims I may have under the laws of the United States or any
state related to the requirements imposed by the aforementioned regulation,
including without limitation a claim for any compensation or other payments I
would otherwise receive, any challenge to the process by which this regulation
was adopted and any tort or constitutional claim about the effect of these
regulations on my employment relationship.

      


      


      
        
          
            
              
                
                  
                    
                      
                        
                          	
                                  Date:

                                	 	 
      	
                                  By

                                	 	 
      
	 
      	 	 
      	
                                  [Name]

                                	 
      
	 
      	 	 
      	
                                  [Title]
UNPUBLISHED

UNITED STATES COURT OF APPEALS 

FOR THE FOURTH CIRCUIT 

No. 08-1747

SUSAN F. KEEVER, 

 Plaintiff - Appellee, 

 v. 

MARTHA MEDLOCK GALLAGHER, 

 Defendant - Appellant. 

Appeal from the United States District Court for the Western 

District of North Carolina, at Charlotte. Martin K. Reidinger, 

District Judge. (3:07-cv-00362-MR) 

Submitted: February 26, 2009 Decided: March 3, 2009 

Before NIEMEYER, MICHAEL, and GREGORY, Circuit Judges. 

Dismissed by unpublished per curiam opinion. 

Thomas B. Kakassy, THOMAS B. KAKASSY, PA, Gastonia, North 

Carolina, for Appellant. Geoffrey A. Planer, Gastonia, North 

Carolina, for Appellee.

Unpublished opinions are not binding precedent in this circuit. 
PER CURIAM: 

Martha Medlock Gallagher appeals the district court’s 

order affirming in part, reversing in part, and remanding to the 

bankruptcy court for further proceedings to determine the nondischargeable portion of a state court tort award. This court 

may exercise jurisdiction only over final orders, 28 U.S.C. 

§ 1291 (2006), and certain interlocutory and collateral orders, 

28 U.S.C. § 1292 (2006); Fed. R. Civ. P. 54(b); Cohen v. 

Beneficial Indus. Loan Corp., 337 U.S. 541 (1949). The order 

Gallagher seeks to appeal is neither a final order nor an 

appealable interlocutory or collateral order. District court 

orders remanding matters to the bankruptcy court for further 

consideration are not final orders. See Legal Representative 

for Future Claimants v. Aetna Cas. & Sur. Co. (In re The Wallace 

& Gale Co.), 72 F.3d 21, 24 (4th Cir. 1995); see also Capitol 

Credit Plan of Tenn., Inc. v. Shaffer, 912 F.2d 749, 750 (4th 

Cir. 1990) (holding that district court order remanding for the 

bankruptcy court to address two arguments not previously 

addressed by the bankruptcy court was not a final decision). 

Accordingly, we dismiss the appeal for lack of jurisdiction. We 

dispense with oral argument because the facts and legal 

2 
3 

contentions are adequately presented in the materials before the 

court and argument would not aid the decisional process. 

DISMISSED
1

NOTICE OF APPEARANCE OF COUNSEL MILES F. EHRLICH, ISMAIL J. RAMSEY, AND AMY E. CRAIG FOR 

NON-PARTY ANTHONY LEVANDOWSKI

Case No. C 17-00939 WHA

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

MILES F. EHRLICH (Bar No. 237954)

miles@ramsey-ehrlich.com

ISMAIL J. RAMSEY (Bar No. 189820)

izzy@ramsey-ehrlich.com

AMY E. CRAIG (SBN 269339)

amy@ramsey-ehrlich.com

RAMSEY & EHRLICH LLP

803 Hearst Avenue

Berkeley, CA 94710

(510) 548-3600 (Tel)

(510) 291-3060 (Fax)

Attorneys for Non-Party Anthony Levandowski

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

SAN FRANCISCO DIVISION

WAYMO LLC,

Plaintiff,

v.

UBER TECHNOLOGIES, INC., et al.,

Defendants.

)

)

)

)

)

)

)

)

)

)

)

)

)

Case No.: C 17-00939 WHA

NOTICE OF APPEARANCE OF 

COUNSEL BY MILES F. EHRLICH, ISMAIL J. RAMSEY AND AMY E. 

CRAIG FOR NON-PARTY 

ANTHONY LEVANDOWSKI

TO THE COURT, ALL PARTIES, AND THEIR COUNSEL OF RECORD: 

PLEASE TAKE NOTICE that Miles F. Ehrlich, Ismail J. Ramsey, and Amy E. Craig of 

Ramsey & Ehrlich LLP hereby enter appearances as counsel of record on behalf of nonparty Anthony Levandowski in the above-captioned matter. 

Mr. Ehrlich is lead attorney on the case. Mr. Ehrlich, Mr. Ramsey, and Ms. Craig

are admitted to practice in the State of California and before this Court. Mr. 

Case 3:17-cv-00939-WHA Document 136 Filed 04/03/17 Page 1 of 2
2

NOTICE OF APPEARANCE OF COUNSEL MILES F. EHRLICH, ISMAIL J. RAMSEY, AND AMY E. CRAIG FOR 

NON-PARTY ANTHONY LEVANDOWSKI

Case No. C 17-00939 WHA

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Levandowski requests that all notices given and all papers filed or served in the abovecaptioned matter be served upon counsel at the address below: 

MILES F. EHRLICH (Cal. Bar No. 237954)

miles@ramsey-ehrlich.com

ISMAIL J. RAMSEY (Bar No. 189820) 

izzy@ramsey-ehrlich.com 

AMY E. CRAIG (SBN 269339)

amy@ramsey-ehrlich.com

RAMSEY & EHRLICH LLP 

803 Hearst Avenue 

Berkeley, CA 94710 

(510) 548-3600 (Tel) 

(510) 291-3060 (Fax)

Dated:April 3, 2017 Respectfully Submitted,

RAMSEY & EHRLICH LLP

//s//

MILES F. EHRLICH

ISMAIL J. RAMSEY

AMY E. CRAIG

Attorneys for Non-Party Anthony Levandowski

Case 3:17-cv-00939-WHA Document 136 Filed 04/03/17 Page 2 of 2
2021

임상시험에 참여하는 여성

= 희망

임상시험은 검사나 치료법이 잘 작용하며 

안전한지 보여주는 것은 돕는 연구입니다. 

귀하가 임상시험에 참여할 수 있는 여러 

방법들이 있습니다. 어떤 임상시험에서는 

귀하가 이미 받고 있는 치료에 대하여 

물어봅니다. 다른 임상시험에서는 새로운 약을 

복용합니다. 어떤 임상시험에서는 건강한 

사람들이 참여합니다. 다른 임상시험에서는 

특정 건강 문제가 있는 사람들이 참여합니다.

여성도 임상시험에 참여합니까?

예, 여성들은 이미 임상시험에 참여하고 있습니다. 그러나 다양한 배경의 여성들이 여전히 참여할 

필요가 있습니다. 모든 연령, 인종 및 민족 단체, 그리고 장애가 있거나 만성 질환을 앓고 있는 

여성들은 임상시험에 참여하는 것에 대하여 생각해 봐야 합니다.

임상시험을 자신을 위해 고려해 볼 수 있습니다. 의사들이 여성의 건강에 대하여 더 알 수 있도록 

도움으로써 영향력을 행사할 수 있습니다. 

왜 여성들이 참여해야 합니까?

의료 제품들은 남성과 여성에게 다르게 영향을 미칠 수 있습니다. 여성은 때때로 다른 부작용을 

겪기 때문에 여성이 임상시험에 참여하는 것이 중요합니다. 여성의 신체는 약 및 장비가 어떻게 

작용하는 지에 영향을 미칠 수 있습니다. 

임상시험이 귀하에게 

맞는지 의료진과 

상담하십시오.

미식품의약국 (FDA)의 여성 보건 부서 (Office of Women’s Health)

www.fda.gov/womeninclinicaltrials

임상시험에 참여하는 여성 (KOREAN)
임상시험에 참여하기 전 알아야 

할 15가지 사항들

임상시험에 참여할 지의 여부는 귀하의 선택에 달려 있습니다. 임상시험에 참여하는 것에 대하여 

압력을 느끼시면 안됩니다. 아무 때에라도 임상시험 참여를 중단할 수 있는 권리가 귀하에게 

있습니다. 임상시험에 참여하는 사람들을 보호하기 위한 규정들이 있습니다. 

제공된 정보 동의서는 임상시험에 참여하기 전 임상시험에 대한 주요 사항들을 알아보는 

과정입니다. 이 목록은 귀하께서 물어보아햐할 전부를 나열하고 있지는 않지만 대화를 시작할 

수 있도록 도움을 줄 것입니다. 참여하기로 동의하기 전에 질문예 대한 답변을 듣을 수 있도록 

확실히 해주십시오. 다음을 알아보십시오:

목적과 앞으로 진행될 일들

1. 임상시험의 목적

2. 귀하가 받을 약, 검사, 그리고 치료

3. 얼마나 오래 임상시험이 진행되며 

얼마나 자주 왕래해야 합니까

4. 어떻게 귀하의 개인 정보가 보호됩니까

5. 임상시험이 끝난 후에는 어떤 일이 

일어납니까.

잠재적 위험과 이점

임상시험은 치료법이나 검사를 제공할 수는 있지만 

귀하의 건강이 호전된다는 보장은 없습니다. 

약, 검사, 혹은 치료가 귀하에게 듣지 않을 수도 

있습니다.

6. 치료법의 이점

7. 치료법의 위험과 부작용

8. 귀하의 병을 앓고 있는 사람들을 위한 

치료법이나 다른 선택 사항

9. 다른 약을 복용할 수 있는 지의 여부

다른 지원 혹은 잠재적인 가격

10.임상시험이 지불해주는 치료 혹은 

서비스 

11. 임상시험이 자녀를 돌보는 것 혹은 교통 

수단을 제공하는 지의 여부

12. 지불해야 하는 돈

13.보험에서 처리해주는 항목

더 많은 정보를 얻기 위한 방법

14. 질문이나 문제가 있을 경우 연락해야할 

사람

15.결과를 받는 방법

미식품의약국 (FDA)의 역할은 무엇입니까?

미식품의약국 (FDA)은 의료 치료법이 사람들에게 안전하고 효과적인지 확인합니다. 

미식품의약국 (FDA)은 새로운 치료법이나 임상시험을 개발하지 않습니다. 

미식품의약국 (FDA) 여성 보건 부서 (Office of Women’s Health)는 미국립보건원 여성 

건강 연구 부서 (NIH Office of Research on Women’s Health)와 협력하여 다양한 배경의 

여성들이 임상시험에 참여하는 것을 독려하기 위한 계획에 참여하고 있습니다. 이러한 

활동들에 대하여 더 많은 정보를 얻기 위해서는 다음을 방문해 주십시오:

www.fda.gov/womeninclinicaltrials
La

menopausia

 las hormonas

www.fda.gov/menopause
La menopausia y las hormonas:

Preguntas para su médico

• ¿Son las hormonas adecuadas para mí? ¿Por qué?

• ¿Cuáles son los beneficios? 

• ¿Cuáles son los riesgos serios y los efectos 

secundarios comunes? 

• ¿Por cuánto tiempo debo usar la terapia hormonal?

• ¿Cuál es la dosis más baja que funcionará para mí? 

• ¿Hay algún medicamento no hormonal que pueda tomar?

RECUERDE: Al usar una terapia hormonal para tratar la menopausia:

• Use la dosis más baja que le ayude. 

• Úsela por el tiempo más corto necesario. 

Para obtener más información acerca de la menopausia y la 

terapia hormonal, visite: www.fda.gov/menopause

OFFICE OF WOMEN’S HEALTH

www.fda.gov/womens
Jamal THOMPSON, petitioner, v. Coco MENDOZA-SALINAS, Warden.

No. 12-9364.

Supreme Court of the United States

May 28, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Christopher COLLIER, Appellant, v. STATE of Florida, Appellee.

Case No. 5D18-2997, 5D18-2998

District Court of Appeal of Florida, Fifth District.

Decision filed July 2, 2019

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 01-11237

Summary Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

NICOLAS LYKOGIORGOS,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Northern District of Texas

USDC No. 2:01-CR-6-1

--------------------

February 27, 2002

Before DeMOSS, PARKER, and DENNIS, Circuit Judges.

PER CURIAM:*

The Federal Public Defender appointed to represent Nicolas

Lykogiorgos has moved for leave to withdraw, filing a motion and

brief pursuant to Anders v. California, 386 U.S. 738 (1967). 

Lykogiorgos has filed a pro se response. The record has not been

adequately developed for this court to consider Lykogiorgos’

ineffective assistance of counsel claims in this direct appeal. 

See United States v. Higdon, 832 F.2d 312, 314 (5th Cir. 1987). 

Our independent review of the record, counsel’s Anders

motion and brief, and Lykogiorgos’ pro se response discloses no
No. 01-11237 

-2-

nonfrivolous issue for appeal. Accordingly, counsel’s motion for

leave to withdraw is GRANTED, counsel is excused from further

responsibilities herein, and the appeal is DISMISSED. See 5TH

CIR. R. 42.2.
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 832 Agreed to Senate (ATS)]

<DOC>

117th CONGRESS
  2d Session
S. RES. 832

  Supporting the designation of September 13, 2022 as National Sepsis 
                                  Day.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           November 15, 2022

 Mr. Schumer submitted the following resolution; which was considered 
                             and agreed to

_______________________________________________________________________

                               RESOLUTION

 
  Supporting the designation of September 13, 2022 as National Sepsis 
                                  Day.

Whereas sepsis is a medical condition caused by a severe immune response to 
        infection or traumatic injury;
Whereas the overwhelming flood of inflammatory signals released into the blood 
        to fight infection can impair blood flow, injuring the body's organs;
Whereas sepsis is a serious infection and a leading cause of death and 
        disability in the Unites States;
Whereas severe sepsis can result in septic shock, exposing the patient to 
        potentially fatal multiple organ failure;
Whereas 1,700,000 people in the United States are infected by sepsis annually;
Whereas sepsis kills 270,000 people in the United States each year;
Whereas sepsis is the most expensive condition treated in hospitals in the 
        United States;
Whereas the number of sepsis deaths is currently on the rise in the United 
        States;
Whereas according to the Centers for Disease Control and Prevention, 80 percent 
        of sepsis cases begin outside the hospital;
Whereas most sepsis fatalities are preventable, and early recognition, 
        diagnosis, and treatment of sepsis can prevent loss of life;
Whereas the sepsis protocols for hospitals in New York State, called ``Rory's 
        Regulations'' for Rory Staunton who died from preventable, treatable 
        sepsis at 12 years of age, have been proven to save lives through rapid 
        identification and treatment of sepsis;
Whereas providers and public health experts should study and learn from Rory's 
        Regulations to find ways to end preventable deaths from sepsis; and
Whereas September 13, 2022, would be an appropriate date to designated as 
        ``National Sepsis Day'' to coincide with the international designation 
        of September 13 as ``World Sepsis Day'', to raise awareness of the 
        condition, to encourage the education of patients, families, health care 
        professionals, and government agencies on the seriousness sepsis and the 
        importance of early detection as the key to survival, and to focus 
        attention and energy towards the ultimate goal of ending sepsis: Now, 
        therefore, be it
    Resolved, That the Senate supports the designation of September 13, 
2022 as ``National Sepsis Day''.
                                 <all>
```
Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert N. Tenczar, as Chief Financial Officer of MMI Products, Inc. (the "Company"), certify, pursuant to 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2005, as filed with the U.S. Securities and Exchange Commission (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|Dated: March 31, 2006 | By:  /s/Robert N. Tenczar        
|--------------------- | ---------------------------------
|                      | Robert N. Tenczar, Vice President
|                      | and Chief Financial Officer of   
|                      | MMI Products, Inc.               































A signed original of this written statement required by Section 906 has been provided to MMI Products, Inc. and will be retained by MMI Products, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
Duane Eugene OWEN, petitioner, v. Michael D. CREWS, Secretary, Florida Department of Corrections, et al.

No. 12-8439.

Supreme Court of the United States

April 29, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.